Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spinocerebellar degeneration.

Susan L Perlman

    Expert Opinion on Pharmacotherapy
    |October 3, 2003
    PubMed
    Summary

    Spinocerebellar ataxias (SCAs) are rare neurological diseases affecting the cerebellum. Current treatments lack FDA-approved drugs, relying on rehabilitation and symptomatic medications.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial.

    JAMA cardiology·2026
    Same author

    Incorporating Patient Perspectives into a Composite Score for Measuring Disease Progression in Spinocerebellar Ataxia (SCA).

    Neurology and therapy·2026
    Same author

    Spinocerebellar Ataxia Progression Measured with the Patient-Reported Outcome Measure of Ataxia.

    Movement disorders : official journal of the Movement Disorder Society·2025
    Same author

    Long-term safety of dexamethasone sodium phosphate encapsulated in autologous erythrocytes in pediatric patients with ataxia telangiectasia.

    Frontiers in neurology·2025
    Same author

    Longitudinal Changes in Patient- and Clinical-Reported Outcomes in Early Spinocerebellar Ataxia Types 1, 2, 3, and 6 from the IDEA Study.

    Movement disorders clinical practice·2025
    Same author

    Racial Disparities in Time to Huntington Disease Diagnosis in North America: An ENROLL-HD Analysis.

    Neurology. Clinical practice·2025

    Area of Science:

    • Neurology
    • Neuroscience
    • Genetics

    Background:

    • Spinocerebellar ataxias (SCAs) encompass a varied group of rare, progressive neurological disorders impacting the cerebellum and its pathways.
    • These inherited conditions often have poorly understood pathophysiology, limited animal models, and a lack of reliable biomarkers.
    • Currently, no universally validated rating scale exists for SCAs in clinical trials.

    Discussion:

    • Clinical trials for ataxia have been limited, with a focus on neurotransmitter mechanisms.
    • There is a significant unmet need for FDA-approved therapeutics for SCAs.
    • Existing management strategies involve rehabilitation and off-label symptomatic medications.

    Key Insights:

    • SCAs represent a significant challenge in neurological research and clinical practice.
    • The absence of validated rating scales and biomarkers hinders therapeutic development.
    • The current treatment landscape for SCAs is restricted to supportive care.

    Outlook:

    • Future research should focus on developing reliable biomarkers and validated rating scales for SCAs.
    • Advancements in understanding SCA pathophysiology are crucial for novel drug development.
    • The development of FDA-approved treatments for SCAs is a critical future goal.

    Related Experiment Videos